Abstract 569P
Background
Artificial intelligence (AI) algorithms have been developed to distinguish MMR-D from MMR-P (proficient) tumors, yet they lack biological interpretability. To address this shortcoming, we used validated AI algorithms to detect and quantify well described morphological features in colon cancers from whole slide images.
Methods
Digital images of stage III colon carcinomas from participants in a phase III trial of FOLFOX-based adjuvant chemotherapy (NCCTG N0147; Alliance) were utilized. Available MMR-D (n=191) and randomly selected MMR-P (n=188) cancers were analyzed. QuantCRC quantifies the amount of stroma and stromal subtypes (immature, mature, inflammatory) and tumor/stroma ratio in addition to grade, mucin, signet ring cells, budding/poorly differentiated clusters (TB/PDC) and tumor-infiltrating lymphocytes (TILs). We also distinguished TILs in epithelium vs stromal using another AI algorithm (Lunit SCOPE IO). Area under the curve (AUC), i.e., discrimination threshold, was measured for each feature to predict MMR status.
Results
Among AI-derived morphological features, significant differences were found by MMR status whereby dMMR cancers had lower immature stroma but higher inflammatory stroma, higher tumor grade, and increased mucin, signet ring cells, tumor size, TB/PDCs, and TILs (all Kruskal-Wallis p<0.05). Univariately, AUC (95% CI) values for prediction of MMR status above 0.6 were as follows: TILs 0.72 (0.67-0.77), immature stroma 0.67 (0.62-0.73); inflammatory stroma 0.67 (0.62-0.73); tumor grade 0.65 (0.60-0.71); signet ring cells 0.65 (0.60-0.71); mucin 0.64 (0.59-0.70). Given that TILs in the overall tumor was most discriminant, we then utilized a TIL-specific AI algorithm measuring TILs in epithelium and stroma and found that epithelial TILs had a significantly higher AUC [ 0.79 (0.74-0.84) compared to stromal TILs 0.58 (0.52-0.63) p<0.0001].
Conclusions
Among morphological tumor features quantified by AI, tumor immature desmoplastic stroma and TILs, particularly epithelial TIL densities, were best able to distinguish MMR-D from MMR-P tumors. These findings have implications for prognosis and subtype-based interventions and can guide spatial molecular interrogation.
Clinical trial identification
NCT00079274.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Supported by Institutional grant support. NIH U10CA180821, U10CA180882, U24CA196171, R01 CA210509 (to FAS). Study NCCTG N0147 received funds from Sanofi.
Disclosure
G. Park, Y. Lim: Financial Interests, Institutional, Member: Lunit. D. Yan, K. Shanmugam: Financial Interests, Institutional, Full or part-time Employment: Roche. C-Y. Ock: Financial Interests, Institutional, Member: Lunit. All other authors have declared no conflicts of interest.
Resources from the same session
518P - Artificial intelligence real-world applications in pediatric neuro-oncology: The AICCELERATE project
Presenter: Federica D'Antonio
Session: Poster session 10
519P - The landscape of PDGFRA mutation in Chinese patients with glioma
Presenter: Qiang Lv
Session: Poster session 10
520P - Copy number variation spectrum analysis of primary glioblastoma
Presenter: Chuandong Cheng
Session: Poster session 10
521P - Deciphering a three-miRNA signature as a prognostic biomarker in glioma patients: Correlation with DFS and OS
Presenter: Ana Belen Diaz Mendez
Session: Poster session 10
522P - Galectin 3 binding protein as potential biomarker in glioma diagnosis
Presenter: Rashmi Rana
Session: Poster session 10
523P - Analysis of DNA damage response (DDR) gene expression as a prognostic factor for glioblastoma patient mortality
Presenter: Alessia-Tara Droesse
Session: Poster session 10
524P - Cell line study of nucleosome-based biomarkers in the diagnosis and detection of relapses in glioblastoma
Presenter: Jonathan Decarpentrie
Session: Poster session 10
525P - Immuno markers in newly glioblastoma patients underwent Stupp protocol after neurosurgery
Presenter: Lorena Gurrieri
Session: Poster session 10
526P - In silico evaluation of the mutational profile of glioblastomas with high expression of PD1, CTLA4 and LAG3 identifies the ERBB-PI3K pathway as a druggable vulnerability target
Presenter: Cristina Saiz-Ladera
Session: Poster session 10
527P - Targetable gene fusions and other alterations in central nervous system tumors assessed by RNA and DNA-based next-generation sequencing
Presenter: LEIMING WANG
Session: Poster session 10